Trial reportScientific reports2025
Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03251300 (Mirabegron for Female Patients With Overactive Bladder Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mirabegron for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of nighttime dosing versus daytime dosing of mirabegron is undetermined. Thus, this study aimed to clarify the effect of nighttime versus daytime mirabegron dosing. Between August 2017 and August 2023, all women with overactive bladder syndrome were randomly assigned to receive mirabegron 25 mg once with nighttime or daytime dosing for 12 weeks. A total of 109 women were enrolled. Fifty-two patients were in the daytime dosing group, and 57 patients were in the nighttime dosing group. Nocturia episodes improved in the nighttime group (5.65 ± 3.71 at baseline versus 4.26 ± 2.60 at 4 weeks, p = 0.019), but not the daytime group. In addition, after 4 weeks of treatment, the nighttime dosing group had a greater benefit in the decrease in urgency episodes at 06:00-12:00 (change: - 2.1 ± 3.7 versus 0.1 ± 2.4, p = 0.003), 18:00-24:00 (change: - 1.4 ± 3.0 versus 0.4 ± 2.7, p = 0.01) and all day (change: - 6.4 ± 10.8 versus 0.1 ± 8.5, p = 0.005), compared to daytime dosing. However, the daytime dosing group had a significant improvement in emotions (change: - 17 ± 25 versus - 6 ± 19, p = 0.006), compared to nighttime dosing. After 12 weeks of treatment, despite the significant improvement in overactive bladder symptoms in both groups, there were no differences between groups. In addition, young age (coefficient = 0.065, p = 0.039) and high baseline Overactive Bladder Symptom Score (OABSS) total score (coefficient = - 0.389, p = 0.002) were independent predictors of the improvement of OABSS total score. In conclusion, mirabegron nighttime dosing appears to benefit women more suffering from nocturia and urgency (especially urgency in the morning), and daytime dosing appears to benefit women with coexistent emotion dysfunction.Trial registration NCT03251300, registered on 16/08/2017. Available at ClinicalTrials.gov, www.clinicaltrials.gov .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.